27 results about "Fat mouse" patented technology

The application discloses a norchizhiol triterpenoid compound, a preparation method and application thereof. The norchizhiol triterpenoid compound norchizhiol A can be quickly prepared from Ganoderma lucidum. The test proves that the norchizhiol A can inhibit the accumulation of triglyceride in the differentiation process of 3T3L1 preadipocytes. The norchizhiol A can also effectively reduce the weight increase and liver coefficient of high-fat-diet-induced obese mice, regulate the blood lipid level of the obese mice, and significantly intervene and improve the lipoprotein distribution of the body. The compound can be used for preparing anti-obesity and lipid-lowering medicines.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.

The invention relates to the technical field of traditional Chinese medicine extracts, in particular to an application of a ligusticum wallichii alcohol extract and an active monomer thereof in preparation of a product for relieving or treating food-borne obesity. Experimental research finds that when the ligusticum wallichii alcohol extract is singly used, the mRNA expression level of POMC in hypothalamus of a high-fat diet induced food-borne obesity mouse can be reduced, the alpha-MSH level in the hypothalamus can be improved, appetite can be effectively inhibited, body weight can be reduced, meanwhile, the number of lipid droplets in the liver can be reduced, and the ligusticum wallichii alcohol extract has the effects of relieving and treating food-borne obesity, preventing and treating hyperlipidemia and the like. And the application potential of liver tissues is improved, and a new direction and theoretical support are provided for treating food-borne obesity and expanding the medication range of ligusticum wallichii.

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of a 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative or its pharmaceutically acceptable salt, or its tautomer, meso compound, racemic compound, enantiomer, diastereomer, or pharmaceutical composition thereof as an active ingredient in the preparation of drugs for the prevention or treatment of obesity and obesity-related metabolic diseases. The 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative of this invention has significant therapeutic effects on obesity and related metabolic diseases. In obese mice induced by a high-fat diet and high-fructose water intake, gavage administration for 6 weeks showed that, compared with the high-fat control group, it inhibited more than 70% of the mice's weight gain, with no significant difference in food intake and water intake, demonstrating good clinical application prospects.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

The application discloses ecdysterone-low molecular weight fructan composite microspheres with fat-reducing and muscle-increasing functions, and a preparation method and application thereof, and belongs to the technical field of biological medicine and functional food. The composite microspheres have a core-shell structure, the inner core is a calcium alginate gel, the outer shell is chitosan, the inner core co-encapsulates ecdysterone and low molecular weight fructan, and the mass ratio of the two is 0.8-1.2:1. The preparation adopts a liquid drop microfluidic technology combined with an internal gelation method to form the inner core, and adopts a post-crosslinking method to coat the outer shell. The composite microspheres are regular in shape, uniform in particle size, high in encapsulation rate, good in stability, excellent in pH response slow-release and anti-degradation characteristics in the gastrointestinal tract. In-vivo pharmacological experiments prove that the composite microspheres can reduce the body weight and body fat rate of obese mice, increase the lean meat content and muscle strength, realize synergistic effects of fat reduction and muscle increase, and can be used for preparing drugs or functional food for improving obesity-related muscle loss, low-muscle obesity and related metabolic syndrome.

The present application relates to the technical field of central obesity related research and treatment, by constructing a central obesity mouse model, it is found that the up-regulation of brain-derived neurotrophic factor (BDNF) expression in adipose tissue is closely related to central obesity resistance. A BDNF fusion polypeptide composed of TAT cell-penetrating peptide, flexible linker and BDNF mature peptide is designed and prepared, the fusion polypeptide has strong cell viability promoting effect at the cellular level, can effectively activate the BDNF signaling pathway and has better stability than natural BDNF protein; an anti-TrkB monoclonal antibody with high affinity and high titer is also prepared. In vivo experiments show that the BDNF fusion polypeptide and its combination with the anti-TrkB monoclonal antibody can effectively inhibit the weight gain of central obesity mice, improve glucose metabolism disorder, increase serum BDNF level and activate the TrkB signaling pathway, and the combination has better synergistic therapeutic effect, which provides a new direction and experimental basis for the treatment of central obesity.

The invention belongs to the technical field of microorganisms, and particularly relates to a strain of Caribik Meyer yeast and application thereof. The strain is isolated from natural plant enzymes. In an in-vitro test, the strain has relatively high TG (Triglyceride) degradation capacity and T-CHO (T-CHO) degradation capacity; in an in-vivo test, the enzyme prepared by fermenting a seed solution of the strain can effectively reduce the weight, fat coefficient and blood fat level of obese mice and relieve pathological changes of fatty liver, has no obvious toxic or side effect, and can be used as a candidate for replacing weight-reducing medicines, so that the enzyme has good practical application value.

The invention belongs to the field of biological medicine, and particularly relates to a construction method and application of a spontaneous obesity model of a systemic GPX3 knock-gene mouse. The construction method comprises the following steps: preparing a precisely targeted GPX3 gene, knocking out a gene editing tool mixture of a specific segment (SEQ ID NO.1) of the GPX3 gene, transferring the gene editing tool mixture into a fertilized egg, and mating a mouse until a stably inherited GPX3 gene knockout homozygous mouse is obtained. The GPX3 is knocked out through the CRISPR / Cas9 technology, the spontaneous obese mouse model which cannot be achieved in the prior art is successfully obtained, the model can simulate obesity-related multi-organ lesions and diabetes mellitus progress, and a reliable tool is provided for obesity mechanism research and drug research and development.

The application discloses a method for relieving obesity cardiomyopathy lipid toxicity by Chemerin and belongs to the technical field of pharmacological research. Mice are selected to establish an obesity mouse model, and are equally divided into a control group, a high-fat diet group, an AAV CMKLR1 virus group, and a high-fat + AAV CMKLR1 virus group. In succession, mouse heart ultrasound, TSE system detection, glucose tolerance test, and insulin tolerance test are carried out, and mouse blood glucose is measured at intervals. Then, tissue protein is extracted for protein immunoblotting, and tissue RNA is extracted for reverse transcription, and then qPCR is used to detect the expression of related genes. After paraffin embedding and slicing of mouse tissues, HE, WGA, immunofluorescence and other pathological staining are carried out. MTBE method is used for lipid extraction and detection of lipid content. ELISA method is used to measure serum Chemerin, and Acyl-RAC method is used to detect protein palmitoylation. Finally, the experimental results are analyzed to draw a conclusion. The present application proves by clinical data and mouse models that Chemerin compensatorily increases in the process of obesity, and Chemerin can relieve cardiac lipid toxicity caused by obesity and protect cardiac function.

The use of an RINL gene and an antagonist thereof in the treatment of obesity. Specifically provided is the use of an RINL gene or an encoded protein thereof. The RINL gene or the encoded protein thereof is used for one of the following: (1) as a marker for diagnosing, detecting or prognosing obesity; (2) in the preparation of a reagent or kit for diagnosing or detecting obesity; or (3) in the preparation of a drug for treating obesity. RINL-KO significantly improves glucose tolerance and insulin resistance of obese mice, ameliorates the accumulation of subcutaneous fat and visceral fat thereof, alleviates the inflammation of adipose tissue thereof, and greatly improves the health of the mice. Therefore, an RINL antagonist has the potential to efficiently treat obesity. It is proposed for the first time that RINL is used as a new target in the preparation of a drug for treating obesity, which is of great significance for new drug screening, and also provides a new idea for the treatment of obesity.

The application relates to the field of biological medicine, and discloses an application of pachyman-derived extracellular vesicles and high-abundance miRNA thereof in relieving obesity. Cell experiments and animal experiments find that the pachyman-derived extracellular vesicles and high-abundance miRNA thereof can up-regulate the expression amount of key genes for brownification of white fat in 3T3-L1 adipocytes and mice in vivo, significantly improve glucose tolerance and insulin resistance of obese mice, and obviously relieve liver steatosis and lipid accumulation. Not only can the pachyman-derived extracellular vesicles and high-abundance miRNA thereof improve obesity from a phenotype, but also can regulate lipid metabolism, and have the value of being applied to preparation of medicines for preventing or relieving obesity and related metabolic complications.

The invention discloses an application of premna microphylla pectin in preparation of a product for preventing and improving diet-induced obesity. The premna pubescens pectin is prepared from premna pubescens leaves as a raw material through extraction, purification and other processes. According to the present invention, the research on the high fat diet induced obese mouse model finds that the body lipid metabolism is regulated by remodeling the intestinal flora structure, particularly reducing the ratio of the phylum firmicutes to the phylum bacteroides, and specifically enriching the beneficial flora such as Muribacaceae and the like by using the premna microphylla pectin; experimental results prove that the premna microphylla pectin can significantly inhibit pathological hypertrophy of adipocytes, reduce visceral fat accumulation, effectively control weight gain and improve dyslipidemia and liver fatty degeneration, and has good biological safety.

The present application relates to a kaurane diterpenoid compound D-33 extracted and separated from the roots of Euphorbia griffithii Hook., a preparation method and uses thereof. Bioactivity tests show that the compound D-33 has a significant weight loss effect in a high-fat diet-induced obese mouse model, can effectively activate uncoupling protein 1 (UCP1) in vitro, and can be used for preparing a thermogenic anti-obesity drug.

The present application relates to a kind of preparation method of corncob polysaccharide and its application as lipid inhibitor.A kind of preparation method of corncob polysaccharide includes the steps of preparing defatted corncob dry powder, alkali extraction crude polysaccharide, enzymatic hydrolysis purification, alcohol precipitation and refining, etc., through defatting, ultrasonic alkali extraction, enzymatic hydrolysis purification, low-temperature alcohol precipitation and freeze-drying etc., realize the efficient preparation of corncob polysaccharide from corncob, improve the comprehensive utilization value of corncob, promote the high-value utilization of bulk agricultural and sideline products;The application of polysaccharide component extracted from corncob as lipid inhibitor is also disclosed, the corncob polysaccharide component of the present application can effectively improve the weight gain and fat deposition of obese mice, providing a new solution for the prevention and treatment of obesity, which can be used as fat substitute or functional food ingredient of low-fat food.

This invention relates to a process for extracting, separating, and refining dietary fiber from bamboo shoots. First, fresh Lei bamboo shoots are peeled, washed, and cut into chunks to obtain block-shaped Lei bamboo shoots. The block-shaped Lei bamboo shoots are then crushed by a crusher to obtain wet granules. The wet granules are then subjected to high-speed double-stage pulping to obtain a pulping liquid. The pulping liquid is then spray-dried to obtain powdered bamboo shoot dietary fiber. The bamboo shoot dietary fiber has an uneven, fluffy structure. The refining process is simple and easy to scale up for industrial production. It can be used as a dietary supplement for mice, exhibiting effects such as weight loss, lowering blood lipids, lowering blood sugar, and lowering cholesterol in high-fat mice. Furthermore, the special high-speed double-stage pulping process significantly increases the surface area of ​​the bamboo shoot dietary fiber, which is beneficial for improving its adsorption properties.

The present disclosure relates to the field of microbial therapy, and specifically to a product for preventing and / or treating obesity and a metabolic syndrome. The product includes a Lactobacillus acidophilus strain JYLA-126 and a coating solution thereof. A bacterial solution of the L. acidophilus strain JYLA-126 is coated with a bacterial coating solution to better transport the bacterial solution to the intestinal tract to exert therapeutic effects. The L. acidophilus strain JYLA-126 coating solution is used for intragastric treatment of obesity mice induced by high-fat diet. Various indicators show that the L. acidophilus strain JYLA-126 coating solution may effectively regulate intestinal microflora and maintain intestinal health. The coating solution improves liver glucose metabolism, reduces liver oxidative stress, improves liver lipid metabolism, and alleviates a liver inflammation level. This coating solution improves white adipose accumulation and promotes brown adipose thermogenesis, thereby achieving effective treatment of obesity and metabolic syndrome in mice.

This invention discloses the application of non-lactolytic streptococci in the preparation of products for preventing obesity, belonging to the field of animal nutrition and feed science and technology. This invention involves preparing non-lactolytic streptococci CCUG41503 into a concentration of 1×10⁻⁶. 8 When a CFU / mL bacterial suspension was administered via gavage to broilers and obese mice, *Streptococcus non-lactolyticus* CCUG41503 reduced abdominal fat percentage and the diameter and area of ​​adipocytes in broilers, and also reduced the weight of epididymal white fat and the diameter and area of ​​adipocytes in obese mice. This indicates that *Streptococcus non-lactolyticus* CCUG41503 has a fat-reducing effect and is widely applicable across multiple species.

The invention discloses application of aucubin in reducing fat deposition, and belongs to the field of biotechnology and animal husbandry application. The new application refers to application of aucubin in preparation of a composition for reducing fat deposition of non-human mammals. In particular, the composition can be used to induce and establish a standardized low fat deposition animal model or state, preferably a high fat diet induced obese mouse model (intragastric dose of 30 mg / kg body weight per day). In addition, the composition can also be used as a feed additive for non-human mammals. The aucubin is developed into a tool for constructing a standardized metabolism scientific research model for the first time, a brand new application scheme is provided for the aucubin as a safe and effective fat deposition regulating agent in livestock production, and the aucubin has important scientific research and industrial value.

The invention relates to the technical field of new application of medicines, and discloses application of nifedipine in preparation of weight-reducing medicines. Specifically, the invention discloses an application of nifedipine in preparation of a product for treating obesity or a product for reducing the weight of animals in a non-disease state, the molecular formula of nifedipine is C17H18N2O6, and experiments find that the weight of obese mice can be effectively reduced through administration treatment of nifedipine; after continuous administration for 8 weeks, the average body weight is reduced by 14.61% relative to the original body weight, and the compound can be used for preparing weight-reducing drugs.

The invention discloses application of nolinoleic acid in preparation of a medicine for treating obesity, and belongs to the technical field of biological medicine. The molecular formula of the nolinoleic acid disclosed by the invention is C17H28O2. The nolinoleic acid plays a positive role in enhancing brown fat heat production and treating obesity, and animal model experiment verification shows that intervention of the nolinoleic acid reduces the weight of obese mice induced by high fat diet, improves the weight of brown fat tissues, improves sugar tolerance and insulin sensitivity, and can be used for treating obesity. And the brown fat heat production function phenotype and the overall metabolism level of mice are increased, which indicates that the nolinoleic acid has an enhancement effect on brown fat heat production and has a certain improvement effect on obesity. The research result of the invention provides a new treatment approach for obesity treatment.

The invention provides a traditional Chinese medicine composition for treating insulin resistance of obese children and a preparation method, and belongs to the technical field of traditional Chinese medicines. According to the traditional Chinese medicine composition, divaricate saposhnikovia roots and wrinkled gianthyssop herbs are used as monarch drugs, fructus gardeniae praeparatus is used as a ministerial drug, rhizoma coptidis and pericarpium citri reticulatae are used as adjuvant drugs, liquorice is used as a conductant drug, rhizoma nardostachyos and bitter herbs are used together, lifting and descending are combined, the effects of purging spleen and stomach fire, clearing damp and heat, eliminating dampness and reducing phlegm and regulating qi activity of the spleen and the stomach are achieved together, middle-jiao fire is cleared, qi activity is regulated, and therefore insulin sensitivity is improved, insulin resistance is improved, and toxic and side effects are reduced. And the physiological characteristic of delicate spleen and stomach of children is considered. When the traditional Chinese medicine composition is used for obese mice, the weight of the obese mice can be effectively reduced, glycolipid metabolism can be optimized, glucose tolerance and insulin resistance can be improved, the pathological morphology of epididymal adipose tissue can be reversed, the diversity of intestinal microbiota of the obese mice with insulin resistance can be increased, and the abundance of beneficial bacteria can be improved.

The application discloses a Chinese medicine external use acupoint patch for treating obesity, which comprises Chinese medicine acupoint hot patching and Chinese medicine acupoint cold patching. The Chinese medicine acupoint hot patching comprises the following raw medicinal materials: atractylodes, atractylodes macrocephala, poria cocos, fried coix seed, dried tangerine or orange peel, cassia twig, asarum and white mustard seed. The Chinese medicine acupoint cold patching comprises the following raw medicinal materials: rhubarb, golden cypress, rhizoma alocasia and borneol. The application adopts specific Chinese medicine compositions to make Chinese medicine acupoint hot patching and Chinese medicine acupoint cold patching, which are respectively applied to the Tian-shu acupoint and the Zu-san-li acupoint and the Qu-chi acupoint. Experimental results show that the patching has obvious regulation effect on the concentration of triglyceride, total cholesterol, free fatty acid and glycerol in the serum of mice, can obviously improve the abnormal blood lipid level of obese mice, and can obviously reduce the subcutaneous and internal fat of mice. The application is external patching, is convenient to use in clinic, and has low adverse reaction.

The invention discloses a probiotic composition with weight-losing efficacy and application thereof.The probiotic composition comprises lactobacillus plantarum HF02, lactobacillus fermentum HF04, lactobacillus plantarum HF09 and alpha-lactalbumin hydrolysis peptide, the viable count ratio of the lactobacillus plantarum HF02 to the lactobacillus fermentum HF04 to the lactobacillus plantarum HF09 is 1: 1: 1, the total viable count is not lower than 1 * 10 < 9 > CFU / mL or 1 * 10 < 9 > CFU / g, and the alpha-lactalbumin hydrolysis peptide is an alpha-lactalbumin hydrolysis peptide. The concentration of the effective component of the alpha-lactalbumin hydrolytic peptide is not less than 0.3 mg / mL. The probiotic composition has the potential of preventing obesity, can effectively improve fat accumulation of the liver of an obese mouse and abnormal blood glucose and insulin levels caused by obesity, reduces weight gain of the mouse induced by high fat diet, and shows a good application prospect.

The invention belongs to the technical field of animal bifidobacterium subsp. Lactis, and particularly relates to an animal bifidobacterium subsp. Lactis WLP90 and application thereof in preparation of a preparation for relieving obesity. The bifidobacterium animalis subsp. Lactis has the performance of targeted inhibition of actinomyces chlamydoides, Enterobacter cancerogenus and Alloscedobacterium animalis, can effectively inhibit pancrelipase, stimulate intestinal cells to generate glucagon-like peptide-1, can effectively improve diseases of obese mice, and can be used for preparing a preparation for relieving obesity.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a substance for promoting METTL3 expression in treatment of obesity adipose tissue inflammation and metabolic diseases. A monomeric compound licoflavone A capable of promoting expression of METTL3 is analyzed from a traditional Chinese medicine prescription, METTL3 is low in expression in obese adipose tissue, and overexpression METTL3 can enable a mouse to be slower in weight increase, higher in insulin sensitivity and improved in glucose tolerance when the mouse is fed with high-fat diet feed, and meanwhile, the average food intake of the mouse every day is not affected; the licoflavone A can remarkably promote protein expression of METTL3, can improve adipocyte inflammation and remarkably improve adipose tissue inflammation of obese mice, and the effect of the licoflavone A in improving the adipose tissue inflammation of the obese mice is verified by detecting inflammation-related gene expression or inflammatory cell infiltration conditions in the adipose tissue of the obese mice.

The invention discloses application of hyodeoxycholic acid in preparation of a medicine for relieving obesity-related subcutaneous metastatic colorectal cancer symptoms, and belongs to the technical field of medical bioengineering. After hyodeoxycholic acid is applied to a constructed obese mouse colorectal cancer subcutaneous metastasis model and intervened by hyodeoxycholic acid, compared with a high-fat diet control group, the volume of subcutaneous transplanted tumor of a mouse is obviously reduced, the damage degree of terminal colon tissue is obviously relieved, and inflammation infiltration and epithelial damage are effectively inhibited. Meanwhile, the intestinal flora structure of the mice in the intervention group is obviously changed, the relative abundance of 9 bacteria genus is obviously increased, and the relative abundance of 18 bacteria genus is obviously reduced. The results show that the hyodeoxycholic acid can relieve tumor load and tissue pathological damage of obesity-related colorectal cancer by adjusting the homeostasis of intestinal flora, so that the treatment effect is achieved. The application of the secondary bile acid in the field of tumor treatment is expanded.